PERIOGARD MOUTHWASH
Land: Canada
Språk: engelsk
Kilde: Health Canada
Preparatomtale
(SPC)
03-12-2019
Noen dokumenter for dette produktet er ikke tilgjengelig for øyeblikket, du kan sende en forespørsel til kundeservicen vår, og vi vil varsle deg så snart vi kan få dem.
Send forespørsel.
Send forespørsel.
Aktiv ingrediens:
CHLORHEXIDINE GLUCONATE
Tilgjengelig fra:
COLGATE-PALMOLIVE CANADA INC
ATC-kode:
A01AB03
INN (International Name):
CHLORHEXIDINE
Dosering :
0.12%
Legemiddelform:
MOUTHWASH
Sammensetning:
CHLORHEXIDINE GLUCONATE 0.12%
Administreringsrute:
BUCCAL
Enheter i pakken:
470ML
Resept typen:
Prescription
Terapeutisk område:
MISCELLANEOUS ANTI-INFECTIVES
Produkt oppsummering:
Active ingredient group (AIG) number: 0107629007; AHFS:
Autorisasjon status:
CANCELLED POST MARKET
Autorisasjon dato:
2018-10-10
Preparatomtale
Page 1 of 19
PRODUCT MONOGRAPH
PERIOGARD
Chlorhexidine Gluconate 0.12% Oral Rinse, USP
Liquid, 0.12% Chlorhexidine Gluconate
Antigingivital Oral Rinse
Colgate-Palmolive Canada Inc. Date of Revision:
Two Morneau Shepell Centre
December 3, 2019
5
th
Floor, 895 Don Mills Road
Toronto, Ontario M3C 1W3
Submission Control No: 232067
Page 2 of 19
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................................
3
SUMMARY PRODUCT INFORMATION
.............................................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................................
3
CONTRAINDICATIONS
.......................................................................................................................
4
WARNINGS AND PRECAUTIONS
.....................................................................................................
4
ADVERSE REACTIONS
.......................................................................................................................
5
DOSAGE AND ADMINISTRATION
.....................................................................................................
6
OVERDOSAGE
.....................................................................................................................................
7
ACTION AND CLINICAL PHARMACOLOGY
.....................................................................................
8
STORAGE AND STABILITY
................................................................................................................
9
SPECIAL HANDLING INSTRUCTIONS
............................................................................................
10
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................................. 10
PART II: SCIENTIFIC INFORMATION
..................................................................................................
11
P
Les hele dokumentet
